Edition:
United Kingdom

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

14.94HKD
23 Feb 2018
Change (% chg)

-- (--)
Prev Close
HK$14.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,755,453
52-wk High
HK$17.90
52-wk Low
HK$7.58

Select another date:

Thu, Feb 22 2018

BRIEF-3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA

* TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​ Source text for Eikon: Further company coverage:

BRIEF-3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​

* UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​ Source text for Eikon: Further company coverage:

BRIEF-3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​

* ‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​ Source text for Eikon: Further company coverage:

BRIEF-3SBio Inc says 601a approved by China FDA for clinical trials ​

* Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​ Source text for Eikon: Further company coverage:

Chinese biopharma 3SBio in $290 million deal for unit of Canada's Therapure

SHANGHAI China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

Chinese biopharma 3SBio in $290 mln deal for unit of Canada's Therapure

SHANGHAI, Sept 4 China's 3SBio Inc has agreed to buy the contract development and manufacturing unit of Canada's Therapure Biopharma Inc for $290 million, part of a push by the Chinese biotech company into the North American market.

Select another date: